biotechne

Recombinant Human MAN1A1 His-tag

Catalog Number: 10665-GH

RDsystems

DESCRIPTION	
Source	Chinese Hamster Ovary cell line, CHO-derived human MAN1A1 protein Pro63-Glu653, with a C-terminal 6-His tag Accession # P33908.3
N-terminal Sequence Analysis	Pro63
Predicted Molecular Mass	67.7 kDa

SPECIFICATIONS		
SDS-PAGE	63-65 kDa, under reducing conditions.	
Activity	Measured by its ability to remove α-mannose from the high mannose glycan Man-9. A distinct band is observed in the rhMAN1A1 digested sample on SDS-PAGE gel, as measured under the described conditions.	
Endotoxin Level	<1.0 EU per 1 µg of the protein by the LAL method.	
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.	
Formulation	Supplied as a 0.2 µm filtered solution in Tris, NaCl and CaCl ₂ . See Certificate of Analysis for details.	

Activity Assay Pro	tocol
Materials	 Digestion Buffer: 50 mM MES, 15 mM CaCl₂, 1 mg/mL BSA, pH 6.0 Labeling Buffer: 25 mM Tris, 150 mM NaCl, 10 mM MnCl₂, pH 7.5 Recombinant Human MAN1A1 (rhMAN-1A1) (Catalog # 10665-GH) Oligomannose-9 (Man-9) (Dextra Laboratories, Catalog # MC1131), 0.1 mg/mL stock in deionized water Recombinant Human MGAT1 (rhMGAT1) (Catalog # 8334-GT) UDP-GlcNAc (Sigma, Catalog # U4375), 50 mM stock in 50% ethanol, 50% deionized water Recombinant Human FUT8 (rhFUT8) (Catalog # 5768-GT) GDP-Cy5-Fucose (Catalog # ES301) 15% SDS-PAGE gel Reducing SDS-PAGE gel loading buffer Fluorescent imager
Assay	Digestion:
	 Dilute rhMAN1A1 to 20 μg/mL in Digestion buffer. Dilute Man-9 to 20 μg/mL in Digestion Buffer. Combine 5 μL of 20 μg/mL Man-9, 5 μL of 20 μg/mL rhMAN1A1 and 10 μL of Digestion Buffer. Include a Control containing 5 μL of 20 μg/mL Man-9 and 15 μL of Digestion Buffer. Incubate at 37 °C for 2 hours.
	Labeling:
	 Dilute rhMGAT1 to 100 μg/mL in Labeling Buffer. Dilute UDP-GlcNAc to 1 mM in Labeling Buffer. Dilute rhFUT8 to 100 μg/mL in Labeling Buffer. Dilute GDP-Cy5-Fucose to 0.05 mM in Labeling Buffer. Transfer 10 μL of each digestion to a new tube and add 5 μL of 100 μg/mL rhMGAT1, 5 μL of 1 mM UDP-GlcNAc, 5 μL of 100 μg/mL rhFUT8 and 5 μL of 0.05 mM GDP-Cy5-Fucose. Incubate at 37 °C for 60 minutes. Add 6 μL of Reducing SDS-PAGE gel loading buffer to each reaction. Load 12 μL of each reaction onto a 15% SDS-PAGE gel and perform electrophoresis. Analyze gel on a fluorescent imager.
Final Assay Conditions	Per Reaction: rhMAN1A1: 0.05 μg Man-9: 0.05 μg rhMGAT1: 0.5 μg UDP-GIcNAc: 5 nmol rhFUT8: 0.5 μg GDP-Cy5-Fucose: 0.25 nmol

PREPARATION AND STORAGE		
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.	
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.	
	 6 months from date of receipt, -20 to -70 °C as supplied. 	
	 3 months, -20 to -70 °C under sterile conditions after opening. 	

DATA

Rev. 11/2/2022 Page 1 of 2



Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956 USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373 Europe | Middle East | Africa TEL +44 (0)1235 529449



Recombinant Human MAN1A1 His-tag

Catalog Number: 10665-GH



BACKGROUND

N-glycan maturation in Golgi apparatus starts with high-mannose glycan Man-9 that is capped with four 1,2-α-linked mannose residues at its non-reducing ends. During the process, these mannose residues are removed to generate Man-5 oligomannose glycan, a precursor for complex and hybrid N-glycans (1). Failure of removing these mannose residues will result in the display of high-mannose glycans on cell surface and extracellular matrix. Increased levels of high-mannose glycans on cell surface are usually associated with disease progress such as tumorigenesis and viral infection (2). The removal of 1,2-α-linked mannose residues are catalyzed by 4 α-mannosidases, including MAN1A1, MAN1B1, MAN1A2 and MAN1C1, that have overlapping substrate specificity and slight differences in enzyme activity (3). MAN1A1 is also a tumor-suppressor (4) and low levels of expression of MAN1A1 correlate with poor prognosis in breast cancer patients (5, 6).

References:

- 1. Oliveira-Ferrer, L. *et al.* (2014) Br. J. Cancer **110**:753.
- 2. Moremen K.W. et al. (2012) Nat. Rev. Mol. Cell Biol. 13:448.
- 3. Moremen, K.W. and Nairn, A.V. (2014) Handbook of Glycosyltransferases and Related Genes p1297.
- 4. Liu, T. et al. (2014) PLoS One 9:e107941.
- 5. Milde-Langosch, K. et al. (2014) Breast Cancer Res. Treat. 145:295.
- 6. Karen Legler, et al. (2018) Br. J. Cancer 118:847.

Rev. 11/2/2022 Page 2 of 2



Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956 USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373 Europe | Middle East | Africa TEL +44 (0)1235 529449